ArticleWorld journal of surgical oncology2026
Serum 5'-tiRNA-iMet-CAT is a novel biomarker for the diagnosis and early postoperative assessment of hepatocellular carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most common digestive system malignancies and a leading cause of cancer-related mortality worldwide. Alpha-fetoprotein (AFP), although widely used, shows limited sensitivity in early HCC, leading to missed diagnoses. Novel molecular markers that complement existing biomarkers are urgently needed. tRNA-derived small RNAs (tsRNAs), a newly recognized class of noncoding RNAs generated from transfer RNAs, are abundant in cancer cells and body fluids and have emerging roles in tumourigenesis. This study aimed to identify dysregulated tsRNAs in HCC and evaluate their clinical value as biomarkers.
methodsWe performed high-throughput sequencing on 3 pairs of HCC tissues and their matched adjacent normal tissues to profile 5'-tiRNA-iMet-CAT, validating its serum levels by quantitative reverse transcription PCR (qRT-PCR). Molecular features and stability were confirmed by electrophoresis, sequencing, and freeze-thaw assays. We assessed clinical correlations, diagnostic potential, and predicted target genes via multiple databases with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis.
resultsSerum 5'-tiRNA-iMet-CAT was significantly elevated in HCC patients versus healthy controls. Its high expression correlated with poor differentiation, larger tumour size, and advanced Barcelona Clinic Liver Cancer stage (all P < 0.05). Receiver operating characteristic analysis confirmed strong diagnostic performance, with levels markedly decreasing postoperatively (P < 0.0001).
conclusionSerum 5'-tiRNA-iMet-CAT is stable, specific, and clinically relevant. It may serve as a promising noninvasive biomarker for HCC diagnosis and evaluating short-term therapeutic response during the early postoperative phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.